The Vanguard Group 13D and 13G filings for Amylyx Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 1:22 pm Unchanged |
2024-09-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
The Vanguard Group | 3,089,645 4.530% |
0 (Unchanged) |
Filing |
| 2024-11-04 10:56 am Sale |
2024-09-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
The Vanguard Group | 3,089,645 4.530% |
-2,185,921 (-41.43%) |
Filing |
| 2024-02-13 4:58 pm Purchase |
2023-12-29 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
The Vanguard Group | 5,275,566 7.810% |
917,074 (+21.04%) |
Filing |
| 2023-02-09 11:07 am Purchase |
2022-12-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
The Vanguard Group | 4,358,492 6.580% |
4,358,492 (New Position) |
Filing |